Development of selective media for the isolation of yeasts and filamentous fungi from the sputum of adult patients with cystic fibrosis (CF)

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Yuriko NaganoJohn E Moore

Abstract

Yeasts and filamentous fungi are beginning to emerge as significant microbial pathogens in patients with cystic fibrosis (CF), particularly in relation to allergic-type responses, as seen in patients with allergic bronchopulmonary aspergillosis (ABPA), Aspergillus bronchitis and in invasive fungal disease in lung transplant patients. Four fungal media were compared in this study, including Sabouraud Dextrose Agar (SDA) and Medium B, with and without the addition of selective antibiotics, where antibiotic-supplemented media were designated with (+). These media were compared for their ability to suppress contaminating, mainly Gram-ve pathogens, in CF sputa (Pseudomonas aeruginosa, Burkholderia cepacia complex [BCC] organisms) and to enhance the growth of fungi present in CF sputum. Medium B consisted of glucose (16.7 g/l), agar (20 g/l), yeast extract (30 g/l) and peptone (6.8 g/l) at pH 6.3 and both SDA(+) and Medium B(+) were supplemented with cotrimethoxazole, 128 mg/l; chloramphenicol, 50 mg/l; ceftazidime, 32 mg/l; colistin, 24 mg/l). Employment of SDA(+) or Medium B(+) allowed an increase in specificity in the detection of yeasts and moulds, by 42.8% and 39.3%, respectively, over SDA when used solely. SDA(+) had a greater ...Continue Reading

References

Feb 14, 2006·Paediatric Respiratory Reviews·Marina Buarque de AlmeidaJoaquim Carlos Rodrigues
Jul 15, 2006·Chest·David ShoseyovEitan Kerem

❮ Previous
Next ❯

Citations

Nov 25, 2014·Proteomics. Clinical Applications·Karthik Shantharam KamathMark P Molloy
Jul 13, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·James A ReihillMadeleine Ennis
Mar 16, 2013·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Jane C LiuErol A Gaillard
Mar 15, 2014·The International Journal of Biochemistry & Cell Biology·Sanjay H Chotirmall, Noel G McElvaney
Mar 15, 2018·Medical Mycology·Carsten SchwarzUNKNOWN ECMM/ISHAM working group Fungal respiratory infections in Cystic Fibrosis (Fri-CF)
Aug 20, 2010·Current Opinion in Pulmonary Medicine·Richard B Moss
Nov 12, 2010·Medical Mycology·Laurie Whittaker Leclair, Deborah A Hogan
Dec 24, 2019·Expert Review of Respiratory Medicine·Jean-Philippe BoucharaGilles Nevez
Sep 18, 2014·Current Opinion in Pulmonary Medicine·Imogen C Felton, Nicholas J Simmonds
Dec 6, 2018·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Tobias G P EngelUNKNOWN Dutch Cystic Fibrosis Fungal Collection Consortium
Oct 24, 2018·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Laurence DelhaesJean-Philippe Bouchara
May 4, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J E Moore, B C Millar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.